home / stock / ppcb / ppcb news

PPCB News and Press, Propanc Biopharma Inc.

Stock Information
Company Name: Propanc Biopharma Inc.
Stock Symbol: PPCB
Market: NASDAQ
Website: propanc.com
Menu
Get PPCB Alerts

News, Short Squeeze, Breakout and More Instantly...
PPCB - Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

MELBOURNE, Australia, March 24, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today annou...
PPCB - Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today annou...

PPCB - Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

MELBOURNE, Australia, March 10, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today annou...

PPCB - Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

MELBOURNE, Australia, March 03, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today highl...
PPCB - Propanc Biopharma, Inc. GAAP EPS of -$0.30

2026-02-18 15:42:43 ET More on Propanc Biopharma, Inc. Seeking Alpha’s Quant Rating on Propanc Biopharma, Inc. Financial information for Propanc Biopharma, Inc. Read the full article on Seeking Alpha For further details see: Propanc Biopharma, Inc....

PPCB - Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

MELBOURNE, Australia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and...

PPCB - Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

MELBOURNE, Australia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today highli...
PPCB - US Companies Moving the Markets, Evening edition
Thu, Jan 29, 2026 as of 4:00 pm ET

A look at the top 10 most actives in the United States ProShares UltraShort Silver -2x Shares (ZSL) rose 7.9% to $1.6933 on volume of 822,800,987 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 2.3% to $1.8001 on volume of 569,291,596 shares Signing Day Sports Inc. (SGN) rose...

PPCB - US Companies Moving the Markets, Morning edition
Thu, Jan 29, 2026 as of 10.00 am ET

A look at the top 10 most actives in the United States ProShares UltraShort Silver -2x Shares (ZSL) fell 8.2% to $1.57 on volume of 657,401,920 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 7.9% to $1.76 on volume of 506,703,633 shares TIAN RUIXIANG Holdings Ltd (TIRX) rose...

PPCB - Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months - Strengthening Global Protection for Breakthrough Proenzyme Formulations

MELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announ...
Next 10